Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

被引:146
作者
Zhu, Feng-Cai [1 ]
Hou, Li-Hua [2 ]
Li, Jing-Xin [1 ]
Wu, Shi-Po [2 ]
Liu, Pei [5 ]
Zhang, Gui-Rong [3 ]
Hu, Yue-Mei [1 ]
Meng, Fan-Yue [1 ]
Xu, Jun-Jie [2 ]
Tang, Rong [1 ]
Zhang, Jin-Long [2 ]
Wang, Wen-Juan [1 ]
Duan, Lei [4 ]
Chu, Kai [1 ]
Liang, Qi [1 ]
Hu, Jia-Lei [1 ]
Luo, Li [5 ]
Zhu, Tao [4 ]
Wang, Jun-Zhi [6 ]
Chen, Wei [2 ]
机构
[1] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China
[2] Beijing Inst Biotechnol, Beijing 100071, Peoples R China
[3] Beijing Inst Drug & Instrument Qual Control, Beijing, Peoples R China
[4] Tianjin CanSino Biotechnol Inc, Tianjin, Peoples R China
[5] Southeast Univ, Dept Publ Hlth, Nanjing, Jiangsu, Peoples R China
[6] Natl Inst Food & Drug Control, Beijing, Peoples R China
关键词
TEST-OF-CONCEPT; SOUTH-AFRICA; T-CELLS; NEUTRALIZING ANTIBODIES; HVTN; 503/PHAMBILI; NONHUMAN-PRIMATES; GENE-THERAPY; HIV VACCINE; VIRUS; IMMUNITY;
D O I
10.1016/S0140-6736(15)60553-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Up to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic strain. Methods We did this randomised, double-blind, placebo-controlled, phase 1 clinical trial at one site in Taizhou County, Jiangsu Province, China. Healthy adults (aged 18-60 years) were sequentially enrolled and randomly assigned (2: 1), by computer-generated block randomisation (block size of six), to receive placebo, low-dose adenovirus type-5 vector-based Ebola vaccine, or high-dose vaccine. Randomisation was pre-stratified by dose group. All participants, investigators, and laboratory staff were masked to treatment allocation. The primary safety endpoint was occurrence of solicited adverse reactions within 7 days of vaccination. The primary immunogenicity endpoints were glycoproteinspecific antibody titres and T-cell responses at day 28 after the vaccination. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, number NCT02326194. Findings Between Dec 28, 2014, and Jan 9, 2015, 120 participants were enrolled and randomly assigned to receive placebo (n=40), low-dose vaccine (n=40), or high-dose vaccine. Participants were followed up for 28 days. Overall, 82 (68%) participants reported at least one solicited adverse reaction within 7 days of vaccination (n=19 in the placebo group vs n=27 in the low-dose group vs n=36 in the high-dose group; p=0.0002). The most common reaction was mild pain at the injection site, which was reported in eight (20%) participants in the placebo group, 14 (35%) participants in the low-dose group, and 29 (73%) participants in the high-dose vaccine group (p<0.0001). We recorded no statistical differences in other adverse reactions and laboratory tests across groups. Glycoprotein-specific antibody titres were significantly increased in participants in the low-dose and high-dose vaccine groups at both day 14 (geometric mean titre 421.4 [95% CI 249.7-711.3] and 820.5 [598.9-1124.0], respectively; p<0.0001) and day 28 (682.7 [424.3-1098.5] and 1305.7 [970.1-1757.2], respectively; p<0.0001). T-cell responses peaked at day 14 at a median of 465.0 spot-forming cells (IQR 180.0-1202.5) in participants in the low-dose group and 765.0 cells (400.0-1460.0) in those in the high-dose group. 21 (18%) participants had mild fever (n=9 in the placebo group, n=6 in the low-dose group, and n=6 in the high-dose group). No serious adverse events were recorded. Interpretation Our findings show that the high-dose vaccine is safe and robustly immunogenic. One shot of the high-dose vaccine could mount glycoprotein-specific humoral and T-cell response against Ebola virus in 14 days.
引用
收藏
页码:2272 / 2279
页数:8
相关论文
共 50 条
  • [21] Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial
    Boffito, Marta
    Fox, Julie
    Bowman, Christine
    Fisher, Martin
    Orkin, Chloe
    Wilkins, Edmund
    Jackson, Akil
    Pleguezuelos, Olga
    Robinson, Stuart
    Stoloff, Gregory A.
    Caparros-Wanderley, Wilson
    VACCINE, 2013, 31 (48) : 5680 - 5686
  • [22] Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
    Ndiaye, Birahim Pierre
    Thienemann, Friedrich
    Ota, Martin
    Landry, Bernard S.
    Camara, Makhtar
    Dieye, Shy
    Dieye, Tandakha Ndiaye
    Esmail, Hanif
    Goliath, Rene
    Huygen, Kris
    January, Vanessa
    Ndiaye, Ibrahima
    Oni, Tolu
    Raine, Michael
    Romano, Marta
    Satti, Iman
    Sutton, Sharon
    Thiam, Aminata
    Wilkinson, Katalin A.
    Mboup, Souleymane
    Wilkinson, Robert J.
    McShane, Helen
    LANCET RESPIRATORY MEDICINE, 2015, 3 (03) : 190 - 200
  • [23] A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants
    Tameris, M.
    Hokey, D. A.
    Nduba, V.
    Sacarlal, J.
    Laher, F.
    Kiringa, G.
    Gondo, K.
    Lazarus, E. M.
    Gray, G. E.
    Nachman, S.
    Mahomed, H.
    Downing, K.
    Abel, B.
    Scriba, T. J.
    McClain, J. B.
    Pau, M. G.
    Hendriks, J.
    Dheenadhayalan, V.
    Ishmukhamedov, S.
    Luabeya, A. K. K.
    Geldenhuys, H.
    Shepherd, B.
    Blatner, G.
    Cardenas, V.
    Walker, R.
    Hanekom, W. A.
    Sadoff, J.
    Douoguih, M.
    Barker, L.
    Hatherill, M.
    VACCINE, 2015, 33 (25) : 2944 - 2954
  • [24] Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial
    Zhu, Fengcai
    Jin, Pengfei
    Zhu, Tao
    Wang, Wenjuan
    Ye, Huayue
    Pan, Hongxing
    Hou, Lihua
    Li, Jingxin
    Wang, Xue
    Wu, Shipo
    Wang, Ying
    Gou, Jinbo
    Huang, Haitao
    Wu, Hongbin
    Wang, Xuewen
    Chen, Wei
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E783 - E791
  • [25] Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial
    Friedman-Klabanoff, DeAnna J.
    Birkhold, Megan
    Short, Mara T.
    Wilson, Timothy R.
    Meneses, Claudio R.
    Lacsina, Joshua R.
    Oliveira, Fabiano
    Kamhawi, Shaden
    Valenzuela, Jesus G.
    Hunsberger, Sally
    Mateja, Allyson
    Stoloff, Gregory
    Pleguezuelos, Olga
    Memoli, Matthew J.
    Laurens, Matthew B.
    EBIOMEDICINE, 2022, 86
  • [26] A randomized, double-blind, placebo-controlled phase I clinical trial of rotavirus inactivated vaccine (Vero cell) in a healthy adult population aged 18-49 years to assess safety and preliminary observation of immunogenicity
    Wu, Jin-Yuan
    Zhang, Wei
    Pu, Jing
    Liu, Yan
    Huang, Li-Li
    Zhou, Yan
    Gao, Jia-Mei
    Tan, Jie-Bing
    Liu, Xin-Ling
    Yang, Jing
    Lin, Xiao-Chen
    Feng, Guang-Wei
    Yin, Na
    Chen, Rong
    Hu, Xiao-Qing
    Yi, Shan
    Ye, Jun
    Kuang, Xiang-Jing
    Wang, Yan
    Zhang, Guang-Ming
    Sun, Mao-Sheng
    Wang, Yan-Xia
    Hu, Zhong-Yu
    Yang, Jing-Si
    Li, Hong-Jun
    VACCINE, 2024, 42 (19) : 4030 - 4039
  • [27] Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo- controlled clinical trial
    Koren, Michael A.
    Lin, Leyi
    Eckels, Kenneth H.
    De La Barrera, Rafael
    Dussupt, Vincent
    Donofrio, Gina
    Sondergaard, Erica L.
    Mills, Kristin
    Robb, Merlin L.
    Lee, Christine
    Adedeji, Oluwaseun
    Keiser, Paul B.
    Curley, Justin M.
    Copeland, Nathanial K.
    Crowell, Trevor A.
    Hutter, Jack N.
    Hamer, Melinda J.
    Valencia-Ruiz, Anais
    Darden, Janice
    Peel, Sheila
    Amare, Mihret F.
    Mebrahtu, Tsedal
    Costanzo, Margaret
    Krebs, Shelly J.
    Gromowski, Gregory
    Jarman, Richard G.
    Thomas, Stephen J.
    Michael, Nelson L.
    Modjarrad, Kayvon
    LANCET INFECTIOUS DISEASES, 2023, 23 (10) : 1175 - 1185
  • [28] Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase I Randomized, Double-Blind, Placebo-Controlled Study
    Li, Li
    Shi, Nianmin
    Xu, Na
    Wang, Haibin
    Zhao, Hui
    Xu, Haidong
    Liu, Dawei
    Zhang, Zheng
    Li, Shuping
    Zhang, Junnan
    Guo, Chunhui
    Huo, Jinglei
    Zhao, Menghan
    Luo, Fengji
    Yang, Liqing
    Bai, Yunhua
    Lu, Qiang
    Zhang, Yusong
    Zhong, Yi
    Gao, Wenhui
    VACCINES, 2022, 10 (11)
  • [29] Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
    Pantaleo, Giuseppe
    Janes, Holly
    Karuna, Shelly
    Grant, Shannon
    Ouedraogo, G. Laissa
    Allen, Mary
    Tomaras, Georgia D.
    Frahm, Nicole
    Montefiori, David C.
    Ferrari, Guido
    Ding, Song
    Lee, Carter
    Robb, Merlin L.
    Esteban, Mariano
    Wagner, Ralf
    Bart, Pierre-Alexandre
    Rettby, Nils
    McElrath, M. Juliana
    Gilbert, Peter B.
    Kublin, James G.
    Corey, Lawrence
    LANCET HIV, 2019, 6 (11): : E737 - E749
  • [30] Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study
    Comeaux, Christy A.
    Bart, Stephan
    Bastian, Arangassery Rosemary
    Klyashtornyy, Vladislav
    De Paepe, Els
    Omoruyi, Edmund
    van der Fits, Leslie
    van Heesbeen, Roy
    Heijnen, Esther
    Callendret, Benoit
    Sadoff, Jerald
    JOURNAL OF INFECTIOUS DISEASES, 2024, 229 (01) : 19 - 29